A phase 2 study of sotorasib in advanced KRAS p.G12C mutated non-small cell lung cancer has delivered promising results including a disease control rate of 80.6%. Dr Bob Li, from the Memorial Sloan Kettering Cancer Centre in the US, presented the results of CodeBreak 100 at the recent IASLC 2020 World Lung Cancer Conference. The ...
KRAS inhibition comes of age for lung cancer?
By Mardi Chapman
3 Feb 2021